Detection of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetics data

Journal of Clinical Pharmacology

Volumn 36, Issue 8, 1996, Pages 752-759

  Yukawa, Eiji ^a,b   Aoyama, Toshinobu ^a  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; PHENOBARBITAL; VALPROIC ACID;

ADOLESCENT; ADULT; ARTICLE; BODY WEIGHT; CHILD; COMPUTER PROGRAM; DRUG CLEARANCE; EPILEPSY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHARMACOEPIDEMIOLOGY; STATISTICAL MODEL;

EID: 0029822952     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04246.x     Document Type: Article

References (16)

1. Bertilsson L: Clinical pharmacokinetics of carbamazepine. Clin Pharmacokinet 1978; 3:263-277.
2. Choonara IA, Rane A: Therapeutic drug monitoring of anticonvulsants: state of the art. Clin Pharmacokinet 1990; 18:318-328.
3. Rey E, D'Athis P, De Lauture D, Dular O, Aicardi J, Olive G: Pharmacokinetics of carbamazepine in the neonate and in the child. Int J Clin Pharmacol Biopharm 1979; 17:90-96.
4. Battino D, Bossi L, Croci D, Francesschetti S, Gomeni C, Moise A, Vitali A: Carbamazepine plasma levels in children and adults: influence of age, dose, and associated therapy. Ther Drug Monit 1980; 2:315-322.
5. Yukawa E, Suzuki A, Higuchi S, Aoyama T: Influence of ago and comedication on steady-state carbamazepine serum level-dose ratios in Japanese paediatric patients. J Clin Pharm Ther 1992; 17:65-69.
6. Summers B, Summers RS: Carbamazepine clearance in paediatric epilepsy patients: influence of body mass, dose, sex and comedication. Clin Pharmacokinet 1989; 17:208-216.
7. Cotter LM, Eadie MJ, Hooper WD, Lander CM, Smith GA, Tyrer JH: The pharmacokinetics of carbamazepine. Eur J Clin Pharmacol 1977; 12:451-456.
8. Rambeck B, May T, Juergens U: Serum concentrations of carbamazepine and its epoxide and diol metabolites in epileptic patients: the influence of dose and co-medication. Ther Drug Monit 1987; 9:298-303.
9. Eichelbaum M, Tomson T, Tybring G, Bertilsson L: Carbamazepine metabolism in man: induction and pharmacogenetic aspects. Clin Pharmacokinet 1985; 10:80-90.
10. Westenberg HGM, Van Der Kleijn E, Oei TT, De Zeeuw RA: Kinetics of carbamazepine and carbamazepine-epoxide determined by use of plasma and saliva. Clin Pharmacol Ther 1978; 23:320-328.
11. Christiansen J, Dam M: Influenece of phenobarbital and diphenylhydantoin on plasma carbamazepine levels in patients with epilepsy. Acta Neurol Scund 1973; 49:543-546.
12. Baciewicz AM: Carbamazepine drug interaction. Ther Drug Monit 1986; 8:305-317.
13. Chang SL, Levy RH: Inhibitory effect of valproic acid on the disposition of carbamazepine and carbamazepine-10,11-epoxide in the rate. Drug Metab Dispos 1986; 14:281-286.
14. Yukawa E: Population-based investigation of carbamazepine relative clearance using routine clinical pharmacokinetic data in Japan: a multiple peak approach feasibility study for pharmacokinetic screening. Clin Drug Invest 1995; 10:29-39.
15. Beal SL, Sheiner LB (eds.): NONMEM Users Guide. San Francisco, CA: NONMEM Project Group, University of California at San Francisco, San Francisco, 1992.
16. Levy RH, Pitlick WH, Troupin AS, Green JR, Neal JM: Pharmacokinetics of carbamazepine in normal man. Clin Pharmacol Ther 1975; 17:657-668.